SECOND-GENERATION PRESCRIPTION ANTIHISTAMINES IN CANADA: AN EVIDENCE-INFORMED REVIEW
Bibliographic record
Abstract
Prescription antihistamines have been available in Canada for over fty years, starting with rst generation medications such as pyrilamine released during World War Two, with the rst second-generation antihistamines commercially appearing in the 1980's. (1) Based on Canadian market growth assessments, antihistamines are an estimated $120 million market, representing over a dozen dedicated prescription and nonprescription (over-the-counter (OTC)) molecules. (2) There are a great number of other non-antihistamine molecules that have direct and indirect afnity for the histamine receptors. (3,4) Secondary to environmental, physiological and co-morbidities, this sector is experiencing an annual growth rate of just under 10%. (2) For registration trials, all antihistamines meet standards and are assessed for non-inferiority against an industry standard such as diphenhydramine. (5,6) Despite having condence regarding non-inferiority across the antihistamines, it is important to go beyond this evidence-based parameter to a patient-focussed evidence-informed approach. (7) This is because not all prescription antihistamines, or necessarily any and all “non-inferiority” medications are created or work alike in the human body. Each molecule has their own molecular “ngerprint” that has physiological and immunological responses through slightly different mechanisms that go beyond histamine mitigation. (8) Evidence-informed medicine allows us to address triggers and cascade management leading to histamine release requires a robust multi-factorial assessment, which includes autoimmune, mast cell, cytokine, and environmental components. (9) Other factors that should be considered include patient specic goals, dietary habits, past allergen exposures, genetics, cross-allergenicity, other medications, and other medical conditions beyond the allergen and subsequent histamine release. (10) Appropriate second-generation antihistamine selection often becomes quite patient-specic and intricate beyond the standard non-inferiority evidence-based histamine mitigation studies. (7,9,10)
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".